|
1
|
Dabigatran versus warfarin in patients with mechanical heart valves.
|
N Engl J Med
|
2013
|
11.14
|
|
2
|
Management and outcomes of major bleeding during treatment with dabigatran or warfarin.
|
Circulation
|
2013
|
2.72
|
|
3
|
The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.
|
Circulation
|
2013
|
2.64
|
|
4
|
Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study.
|
Circulation
|
2013
|
2.48
|
|
5
|
Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification.
|
J Mol Cell Cardiol
|
2004
|
2.23
|
|
6
|
Pharmacologic cholinesterase inhibition improves survival in experimental sepsis.
|
Crit Care Med
|
2008
|
2.18
|
|
7
|
Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial.
|
Circulation
|
2012
|
2.18
|
|
8
|
Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial.
|
Circulation
|
2012
|
1.83
|
|
9
|
Matrix-metalloproteinases and their inhibitors are elevated in severe sepsis: prognostic value of TIMP-1 in severe sepsis.
|
Scand J Infect Dis
|
2006
|
1.65
|
|
10
|
Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
|
Thromb Haemost
|
2012
|
1.51
|
|
11
|
Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial.
|
Eur J Heart Fail
|
2013
|
1.50
|
|
12
|
Interleukin-1 beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis.
|
Atherosclerosis
|
2003
|
1.49
|
|
13
|
Comprehensive risk reduction in patients with atrial fibrillation: emerging diagnostic and therapeutic options--a report from the 3rd Atrial Fibrillation Competence NETwork/European Heart Rhythm Association consensus conference.
|
Europace
|
2011
|
1.35
|
|
14
|
Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis.
|
Cardiovasc Pathol
|
2005
|
1.35
|
|
15
|
Diagnostic and prognostic utility of soluble CD 14 subtype (presepsin) for severe sepsis and septic shock during the first week of intensive care treatment.
|
Crit Care
|
2014
|
1.26
|
|
16
|
A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
|
Am Heart J
|
2012
|
1.22
|
|
17
|
Perioperative bridging anticoagulation during dabigatran or warfarin interruption among patients who had an elective surgery or procedure. Substudy of the RE-LY trial.
|
Thromb Haemost
|
2014
|
1.22
|
|
18
|
Expression of bone sialoprotein and bone morphogenetic protein-2 in calcific aortic stenosis.
|
J Heart Valve Dis
|
2004
|
1.20
|
|
19
|
Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competence NETwork/European Heart Rhythm Association consensus conference.
|
Europace
|
2013
|
1.16
|
|
20
|
Tumor necrosis factor alpha promotes an osteoblast-like phenotype in human aortic valve myofibroblasts: a potential regulatory mechanism of valvular calcification.
|
Int J Mol Med
|
2005
|
1.09
|
|
21
|
Systemic and local levels of fetuin-A in calcific aortic valve stenosis.
|
Int J Mol Med
|
2007
|
1.02
|
|
22
|
Matrix metalloproteinases and their inhibitors: promising novel biomarkers in severe sepsis?
|
Crit Care
|
2009
|
0.94
|
|
23
|
Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
|
J Am Coll Cardiol
|
2012
|
0.93
|
|
24
|
Xenon and isoflurane differentially modulate lipopolysaccharide-induced activation of the nuclear transcription factor KB and production of tumor necrosis factor-alpha and interleukin-6 in monocytes.
|
Anesth Analg
|
2004
|
0.91
|
|
25
|
Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure.
|
Eur J Heart Fail
|
2013
|
0.90
|
|
26
|
Influence of receptor activator of nuclear factor kappa B on human aortic valve myofibroblasts.
|
Exp Mol Pathol
|
2005
|
0.89
|
|
27
|
Prospective study of interleukin-6 and the risk of malignant ventricular tachyarrhythmia in ICD-recipients--a pilot study.
|
Cytokine
|
2007
|
0.88
|
|
28
|
Role of proinflammatory markers and NT-proBNP in patients with an implantable cardioverter-defibrillator and an electrical storm.
|
Cytokine
|
2009
|
0.88
|
|
29
|
Transforming growth factor beta 1 (TGF-beta 1) in atrial fibrillation and acute congestive heart failure.
|
Clin Res Cardiol
|
2010
|
0.87
|
|
30
|
Representativeness of the dabigatran, apixaban and rivaroxaban clinical trial populations to real-world atrial fibrillation patients in the United Kingdom: a cross-sectional analysis using the General Practice Research Database.
|
BMJ Open
|
2012
|
0.86
|
|
31
|
Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
|
Curr Med Res Opin
|
2012
|
0.85
|
|
32
|
Alterations of leptin in the course of inflammation and severe sepsis.
|
BMC Infect Dis
|
2012
|
0.85
|
|
33
|
Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction.
|
Cardiology
|
2003
|
0.84
|
|
34
|
Diagnostic performance and cost effectiveness of measurements of plasma N-terminal pro brain natriuretic peptide in patients presenting with acute dyspnea or peripheral edema.
|
Int J Cardiol
|
2008
|
0.83
|
|
35
|
Levels of oxidized low-density lipoproteins are increased in patients with severe sepsis.
|
J Crit Care
|
2008
|
0.83
|
|
36
|
High plasma levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and interleukin-8 (IL-8) characterize patients prone to ventricular fibrillation complicating myocardial infarction.
|
Clin Chem Lab Med
|
2007
|
0.82
|
|
37
|
Increased plasma levels of NT-proANP and NT-proBNP as markers of cardiac dysfunction in septic patients.
|
Clin Lab
|
2005
|
0.81
|
|
38
|
Statin therapy of calcific aortic stenosis: hype or hope?
|
Eur Heart J
|
2006
|
0.81
|
|
39
|
A new language of natriuretic peptides in sepsis?
|
Crit Care Med
|
2008
|
0.80
|
|
40
|
Alterations of adiponectin in the course of inflammation and severe sepsis.
|
Shock
|
2012
|
0.80
|
|
41
|
Long-term prognostic value of mid-regional pro-adrenomedullin and C-terminal pro-endothelin-1 in patients with acute myocardial infarction.
|
Clin Chem Lab Med
|
2008
|
0.80
|
|
42
|
Connective tissue growth factor (CTGF/CCN2): diagnostic and prognostic value in acute heart failure.
|
Clin Res Cardiol
|
2013
|
0.78
|
|
43
|
Association of NT-proBNP with severity of heart valve disease in a medical patient population presenting with acute dyspnea or peripheral edema.
|
J Heart Valve Dis
|
2008
|
0.78
|
|
44
|
Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
|
Int J Cardiol
|
2007
|
0.78
|
|
45
|
Diagnostic performance of mid-regional pro-adrenomedullin as an analyte for the exclusion of left ventricular dysfunction.
|
Int J Cardiol
|
2007
|
0.78
|
|
46
|
Prognostic value of natriuretic peptides in severe sepsis.
|
Crit Care Med
|
2007
|
0.77
|
|
47
|
Decreased plasmalogen concentration as a surrogate marker of oxidative stress in patients presenting with acute coronary syndromes or supraventricular tachycardias.
|
Clin Chem Lab Med
|
2007
|
0.77
|
|
48
|
Time-course of neopterin levels in patients suffering from severe sepsis treated with and without Drotrecogin-alpha (activated).
|
Scand J Infect Dis
|
2008
|
0.77
|
|
49
|
Anticoagulant-related gastrointestinal bleeding--could this facilitate early detection of benign or malignant gastrointestinal lesions?
|
Ann Med
|
2014
|
0.77
|
|
50
|
New horizons: NT-proBNP for risk stratification of patients with shock in the intensive care unit.
|
Crit Care
|
2006
|
0.77
|
|
51
|
Pathogenetic role of Chlamydia pneumoniae in calcific aortic stenosis: immunohistochemistry study and review of the literature.
|
J Heart Valve Dis
|
2003
|
0.77
|
|
52
|
Elevation of the glycoxidation product N(epsilon)-(carboxymethyl)lysine in patients presenting with acute myocardial infarction.
|
Clin Chem Lab Med
|
2009
|
0.76
|
|
53
|
Effect of clopidogrel on adhesion molecules, hemostasis, and fibrinolysis in coronary heart disease.
|
J Cardiovasc Pharmacol
|
2008
|
0.76
|
|
54
|
Beyond sepsis: activated protein C and heat stroke.
|
Crit Care Med
|
2006
|
0.76
|
|
55
|
Reply: Anticoagulant-Related Nephropathy.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
56
|
Letter regarding article by Franscini et al, "gene expression profiling of inflamed human endothelial cells and influence of activated protein C".
|
Circulation
|
2005
|
0.75
|
|
57
|
Dabigatran in patients with mechanical heart valves.
|
N Engl J Med
|
2014
|
0.75
|
|
58
|
Letter by Van de Werf et al regarding article, "using dabigatran in patients with stroke: a practical guide for clinicians".
|
Stroke
|
2012
|
0.75
|
|
59
|
[Chlamydia pneumoniae--a new risk factor for calcific aortic stenosis?].
|
Med Klin (Munich)
|
2005
|
0.75
|
|
60
|
Dabigatran treatment simulation in patients undergoing maintenance haemodialysis.
|
Thromb Haemost
|
2015
|
0.75
|
|
61
|
Time course of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients presenting with acute coronary syndrome.
|
Clin Chem Lab Med
|
2005
|
0.75
|
|
62
|
Drotrecogin alfa (activated) prolongs half-life time of messenger RNA encoding for interleukin-8 and monocyte chemoattractant protein-1.
|
Thromb Haemost
|
2003
|
0.75
|
|
63
|
Diagnostic and Long-Term Prognostic Value of Sensitive Troponin I in Symptomatic Patients Suspected of Acute Heart Failure.
|
Clin Lab
|
2015
|
0.75
|
|
64
|
Enhanced proinflammatory response of mononuclear cells to in vitro LPS-challenge in patients with ventricular fibrillation in the setting of acute myocardial infarction.
|
Cytokine
|
2008
|
0.75
|
|
65
|
Comparison of long-term prognostic value of N-terminal-proBNP and midregional-pro-adrenomedullin in patients with acute myocardial infarction.
|
Clin Lab
|
2010
|
0.75
|